SCHEMBL4515148

SCHEMBL4515148

Cc1ccccc1CN1CCN(Cc2ccccc2C#N)C1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLPP Q16740 1/20 0.57
MEN1 O00255 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
KDM4E B2RXH2 2/20 0.52
P2RX7 Q99572 2/20 0.51
MAPT P10636 2/20 0.50
PRMT5 O14744 2/20 0.48
WDR77 Q9BQA1 2/20 0.48
ALDH1A1 P00352 3/20 0.48
LMNA P02545 2/20 0.48
C5AR1 P21730 1/20 0.47
TSHR P16473 3/20 0.47
GLA P06280 1/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
BRD4 O60885 1/20 0.44
PTGS1 P23219 1/20 0.44
PTGS2 P35354 1/20 0.44
SIRT2 Q8IXJ6 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4512688 0.87 KMT2A (0.65) MEN1KMT2ASMN1; SMN2KDM4EP2RX7
SCHEMBL4525369 0.83 MEN1 (0.55) CLPPMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4515572 0.81 MAPT (0.67) MEN1KMT2ASMN1; SMN2KDM4EP2RX7
SCHEMBL3728938 0.80 P2RX7 (0.74) P2RX7
SCHEMBL4503890 0.80 CLPP (0.58) CLPPMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4523295 0.80 CYP1A2 (0.64) MEN1KMT2ASMN1; SMN2KDM4EP2RX7
SCHEMBL4511636 0.80 KDM4E (0.66) CLPPMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4511608 0.77 KMT2A (0.52) CLPPMEN1KMT2ASMN1; SMN2KDM4E
SCHEMBL4513866 0.75 KDM4E (0.57) MEN1KMT2ASMN1; SMN2KDM4EP2RX7
SCHEMBL4519320 0.75 KMT2A (0.55) MEN1KMT2ASMN1; SMN2KDM4EP2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-10-22 US disclosed
EP-1864971-A1 PROPHYLACTIC/THERAPEUTIC AGENT FOR DIABETES Takeda Pharmaceutical Company Limited (JP) 2007-12-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264650-A1 Prophylactic/Therapeutic Agent for Diabetes HSD11B1, HSD17B1, HSD11B2 CLPP 4508/4885MEN1 1254/4885KMT2A 2379/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.